(MedPage Today) — Rituximab (Rituxan) prevented relapse in patients with adult-onset frequently relapsing nephrotic syndrome (FRNS) or steroid-dependent nephrotic syndrome (SDNS), a randomized trial showed.
Among 66 adults, 87.4% of those treated…
Source link : https://www.medpagetoday.com/nephrology/generalnephrology/118319
Author :
Publish date : 2025-11-05 16:06:00
Copyright for syndicated content belongs to the linked Source.
